# FDA Approves Sacituzumab Govitecan Plus Pembrolizumab as First-Line Therapy for PD-L1-Positive Triple-Negative Breast Cancer

> fda · REPORTED · 2026-07-31

The FDA approved sacituzumab govitecan-hziy, alone or in combination with pembrolizumab, as a first-line therapy for unresectable or metastatic triple-negative breast cancer (TNBC) in PD-L1-positive patients. This approval marks a significant advance in first-line TNBC management, combining an antibody-drug conjugate with a checkpoint inhibitor.

About FDA / Sacituzumab Govitecan (Gilead/Immunomedics): Sacituzumab govitecan is an antibody-drug conjugate targeting Trop-2 developed for difficult-to-treat breast cancers; pembrolizumab is Merck's PD-1 checkpoint inhibitor, both used together in metastatic TNBC.

- Company: FDA / Sacituzumab Govitecan (Gilead/Immunomedics)
- Sector: oncology
- Primary source: https://www.targetedonc.com/clinical/breast

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.